CP and small cell lung carcinoma: In addition, anlotinib was evaluated in first-line in a placebo-controlled randomized phase III trial in patients with ES-SCLC to receive anlotinib/benmelstobart (an anti-PDL1) plus CP/EP, or anlotinib/placebo plus CP/EP, or placebo/placebo plus CP/EP.